FDA Approves FluMist's Use in Young Children - - BioPharm International


FDA Approves FluMist's Use in Young Children

BioPharm Bulletin

The US Food and Drug Administration has approved the use of the nasal influenza vaccine FluMist in children ages 2–5. Approval for the vaccine was previously limited to healthy children 5 years of age and older and adults up to age 49.

Before this approval, there were only two vaccines licensed in the US for children under the age of 5. One of the vaccines, Fluzone, is indicated for people over 6 months of age, while Fluvirin, the other vaccine, is for use in children age 4 and older.

FDA release

blog comments powered by Disqus



Novartis Reports Positive Results for Secukinumab in Ankylosing Spondylitis Trials
October 23, 2014
Pall ForteBio Releases Bioprocessing Contamination Detection Kit
October 22, 2014
Roche to Expand and Improve its Basel Site
October 22, 2014
FDA Panel Unanimously Backs Secukinumab for the Treatment of Psoriasis
October 22, 2014
EMA Works to Speed Up Ebola Treatment
October 20, 2014
Author Guidelines
Source: BioPharm Bulletin,
Click here